Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy 10, pages 465-481.
Read now
Read now
Vedat Uygun & Erdal Kurtoglu. (2013) Iron-chelation therapy with oral chelators in patients with thalassemia major. Hematology 18:1, pages 50-55.
Read now
Read now
George J. Kontoghiorghes. (2011) A Record Of 1320 Suspect, Deferasirox-Related, Patient Deaths Reported In 2009: Insufficient Toxicity Testing, Low Efficacy And Lack Of Transparency May Endanger The Lives Of Iron Loaded Patients. Hemoglobin 35:3, pages 301-311.
Read now
Read now
Krittapoom Akrawinthawong, Nithima Chaowalit, Thanasaporn Chatuparisuth & Noppadol Siritanaratkul. (2011) Effectiveness of deferiprone in transfusion‐independent beta‐thalassemia/HbE patients. Hematology 16:2, pages 113-122.
Read now
Read now
George J Kontoghiorghes. (2010) Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities. Expert Opinion on Drug Safety 9:4, pages 633-641.
Read now
Read now
George J. Kontoghiorghes. (2009) A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients. Hemoglobin 33:5, pages 332-338.
Read now
Read now
Anita Kolnagou & George J. Kontoghiorghes. (2009) Advances in the Prevention and Treatment are Changing Thalassemia from a Fatal to a Chronic Disease. Experience from a Cyprus Model and its Use as a Paradigm for Future Applications. Hemoglobin 33:5, pages 287-295.
Read now
Read now
George J Kontoghiorghes. (2008) Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients. Expert Opinion on Drug Safety 7:6, pages 645-646.
Read now
Read now
John B. Porter, Ali T. Taher, Maria D. Cappellini & Elliott P. Vichinsky. (2008) Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1–2):1–15.]. Hemoglobin 32:6, pages 601-607.
Read now
Read now
George J. Kontoghiorghes. (2008) Transparency and Access to Full Information for the Fatal or Serious Toxicity Risks, Low Efficacy and High Price of Deferasirox, Could Increase the Prospect of Improved Iron Chelation Therapy Worldwide. Hemoglobin 32:6, pages 608-615.
Read now
Read now
Articles from other publishers (25)
Marjan Abedi & Soheila Rahgozar. (2022) Puzzling out iron complications in cancer drug resistance. Critical Reviews in Oncology/Hematology 178, pages 103772.
Crossref
Crossref
George J. Kontoghiorghes. (2022) Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients. International Journal of Molecular Sciences 23:3, pages 1364.
Crossref
Crossref
Anna L. Greenshields, Melanie R. Power Coombs, Wasundara Fernando, Bruce E. Holbein & David W. Hoskin. (2019) DIBI, a novel 3-hydroxypyridin-4-one chelator iron-binding polymer, inhibits breast cancer cell growth and functions as a chemosensitizer by promoting S-phase DNA damage. BioMetals 32:6, pages 909-921.
Crossref
Crossref
Reza Heidari. (2019) The footprints of mitochondrial impairment and cellular energy crisis in the pathogenesis of xenobiotics-induced nephrotoxicity, serum electrolytes imbalance, and Fanconi’s syndrome: A comprehensive review. Toxicology 423, pages 1-31.
Crossref
Crossref
Michaela Jung, Christina Mertens, Elisa Tomat & Bernhard Brüne. (2019) Iron as a Central Player and Promising Target in Cancer Progression. International Journal of Molecular Sciences 20:2, pages 273.
Crossref
Crossref
Yafang Wang, Lei Yu, Jian Ding & Yi Chen. (2018) Iron Metabolism in Cancer. International Journal of Molecular Sciences 20:1, pages 95.
Crossref
Crossref
Samira Heydarian, Reza Jafari & Hosein Karami. (2015) Refractive errors and ocular biometry components in thalassemia major patients. International Ophthalmology 36:2, pages 267-271.
Crossref
Crossref
Somayeh Kalanaky, Maryam Hafizi, Sepideh Safari, Kazem Mousavizadeh, Mahboubeh Kabiri, Alireza Farsinejad, Saideh Fakharzadeh & Mohammad Hassan Nazaran. (2016) TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo. International Journal of Hematology 103:3, pages 274-282.
Crossref
Crossref
Christina N Kontoghiorghe & George J Kontoghiorghes. (2016) New developments and controversies in iron metabolism and iron chelation therapy. World Journal of Methodology 6:1, pages 1.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
838
839
.
Reza Jafari, Samira Heydarian, Hosein Karami, MohammadMomeni Shektaei, KiumarsNoruzpour Dailami, AhmadAhmadzadeh Amiri, MajidReza Sheikh Rezaee & AsadAllah Farrokh Far. (2015) Ocular abnormalities in multi-transfused beta-thalassemia patients. Indian Journal of Ophthalmology 63:9, pages 710.
Crossref
Crossref
Annita Kolnagou. (2014) Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World Journal of Methodology 4:4, pages 197.
Crossref
Crossref
Christina N Kontoghiorghe. (2014) World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World Journal of Methodology 4:3, pages 163.
Crossref
Crossref
Janice E. Sullivan & Mark J. McDonald. 2014. Pediatric Critical Care Medicine. Pediatric Critical Care Medicine
695
727
.
David P. Steensma. (2011) The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate. Current Hematologic Malignancy Reports 6:2, pages 136-144.
Crossref
Crossref
Efthimia VlachakiK. Chatzinikolaou, E. Bekiari, F. Klonizakis & A. Tsapas. (2011) Is Deferasirox Implicated in Multiple Organ Failure in a Patient With Homozygous β-Thalassemia?. Angiology 62:4, pages 346-348.
Crossref
Crossref
Hsin-Yi Wei, Chao-Ping Yang, Chi-Hui Cheng & Fu-Sung Lo. (2011) Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months. Transfusion 51:5, pages 949-954.
Crossref
Crossref
Annita Kolnagou, Marios Kleanthous & George J. Kontoghiorghes. (2010) Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. European Journal of Haematology 85:5, pages 430-438.
Crossref
Crossref
Joanne Yacobovich, Pinhas Stark, Shlomit Barzilai-Birenbaum, Irit Krause, Idit Pazgal, Isaac Yaniv & Hannah Tamary. (2010) Acquired Proximal Renal Tubular Dysfunction in β-Thalassemia Patients Treated With Deferasirox. Journal of Pediatric Hematology/Oncology 32:7, pages 564-567.
Crossref
Crossref
Alfonso Gutiérrez Macías, Eva Lizarralde Palacios, Itziar Olabarría Santurtún & Pedro Martínez Odriozola. (2010) Síndrome de hipersensibilidad retardada inducido por deferasirox. Medicina Clínica 134:7, pages 329-330.
Crossref
Crossref
David Rodriguez-Lucena, François Gaboriau, Freddy Rivault, Isabelle J. Schalk, Gérard Lescoat & Gaëtan L.A. Mislin. (2010) Synthesis and biological properties of iron chelators based on a bis-2-(2-hydroxy-phenyl)-thiazole-4-carboxamide or -thiocarboxamide (BHPTC) scaffold. Bioorganic & Medicinal Chemistry 18:2, pages 689-695.
Crossref
Crossref
Zakaria Mohammad Al Hawsawi, Mona Hamza Sairafy, Ahmed Mohamed Tarawah, Mohammed Adnan Zolaly & Abdul Rahman Soad Al Hegaily. (2010) Experience with Combination Therapy of Deferiprone and Desferrioxamine in β-Thalassemia Major Patients with Iron Overload at Maternity and Children Hospital, Al Madinah Al Munawarah, Saudi Arabia. Journal of Taibah University Medical Sciences 5:1, pages 27-35.
Crossref
Crossref
R.H.B. Meyboom. 2010. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions. Side Effects of Drugs Annual 32 - A worldwide yearly survey of new data and trends in adverse drug reactions and interactions
425
435
.
Cédric Rafat, Fadi Fakhouri, Jean-Antoine Ribeil, Richard Delarue & Moglie Le Quintrec. (2009) Fanconi Syndrome Due to Deferasirox. American Journal of Kidney Diseases 54:5, pages 931-934.
Crossref
Crossref
David P. Steensma. (2009) Myelodysplasia paranoia: Iron as the new radon. Leukemia Research 33:9, pages 1158-1163.
Crossref
Crossref